U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market To Reach $5.59 Billion By 2030

U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Growth & Trends

The U.S. generic injectables pharmaceutical contract manufacturing market size is expected to reach USD 5.59 billion by 2030, according to a new report by Grand View Research, Inc. The U.S. market is expected to expand at a CAGR of 10.8% from 2025 to 2030. Key factors driving the growth of this market are the rising frequency of patent expirations for blockbuster drugs, streamlined regulatory pathways, low cost of generics, and increasing penetration of CDMOs in the generic injectables space.

The COVID-19 pandemic significantly impacted the supply chain market and its management, including the U.S. generic injectables pharmaceutical contract manufacturing sector. The conduction of clinical trials for new generic injectables has been modified or delayed due to pandemic-related safety concerns and restrictions, potentially impacting the development timeline. Furthermore, several pharmaceutical companies pivoted their production capacities to manufacture COVID-19 vaccines, significantly impacting the production timelines and capacity for other pharmaceuticals, including generic injectables.

The increasing number of patent expirations for biologic injectables is a key factor contributing to the growth of the generic injectables market in the country. For instance, as per the U.S. FDA, the blockbuster injectable drug Humira, developed by AbbVie Inc. that treats the symptoms of Crohn’s disease, arthritis, plaque psoriasis, and Ankylosing Spondylitis, has lost its patent in 2023. This expiration has paved the way for introducing its generic counterpart, adalimumab. The rising demand for generics owing to their cost-effectiveness is another significant factor contributing to the growth of the U.S. market for generic injectables pharmaceutical contract manufacturing.

 Request a free sample copy or view report summary: U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Report

U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Report Highlights

• On the basis of molecule segment, the market is segregated into small molecule, and large molecule. In 2024, the large molecule segment dominated the market, accounting for a revenue share of 58.02%.

• The small molecule segment is anticipated to register the CAGR of 10.40% during the forecast period. Small molecule-based injectable drugs continue to hold an essential position in the treatment of a wide range of illnesses, including cancer, blood disorders, infectious diseases, and cardiovascular ailments.

• On the basis of application segment, the market is segregated into oncology, immunology, antidiabetic, neurology, cardiovascular, respiratory, and others. In 2024, the oncology segment dominated the market, accounting for a revenue share of 29.42%.

• The neurology segment is anticipated to register the fastest CAGR of 11.64% during the forecast period.

U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Segmentation

Grand View Research has segmented U.S. generic injectables pharmaceutical contract manufacturing market report based on molecule and application:

U.S. Generic Injectables Pharmaceutical Contract Manufacturing Molecule Outlook (Revenue, USD Million, 2018 - 2030)

• Small Molecule

• Large Molecule

U.S. Generic Injectables Pharmaceutical Contract Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

• Immunology

• Antidiabetic

• Neurology

• Cardiovascular

• Respiratory

• Others

List of Key Players of U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market

• Hikma Pharmaceuticals PLC

• Pfizer Inc.

• Fresenius Kabi

• Sandoz AG

• Jubilant Pharma Limited

• Baxter

• PCI Pharma Services

• Gland Pharma Limited (USA)

• Dr.Reddy’s Laboratories Ltd.

• Grand River Aseptic Manufacturing